Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes - sprookjes - yvandenbroek - TriplyDB

Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes

Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes

http://www.wikidata.org/entity/Q34341759

about

Role of insulin in the type 2 diabetes therapy: past, present and future Advances in salivary gland gene therapy - oral and systemic implications Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.

P2860

Q22241148-892C6D9F-2F77-4FD5-9E97-70DD9CF53E2E Q28084318-8C4772D1-7CC3-4226-923B-FBEF33627C85 Q34068305-B20CB03D-7033-4525-A24D-D50A8AF786FF

P2860

Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes

http://www.wikidata.org/entity/Q34341759

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@ast

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@en

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@nl

type

label

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@ast

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@en

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@nl

prefLabel

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@ast

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@en

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@nl

P1433

Q34341759-32514BC4-53C9-4DF1-AED8-6C3ECC0677C4

P1476

Q34341759-10776F3C-F6AE-4743-990A-438D0D19AA7B

P2093

Q34341759-00CA8917-B435-4B01-87AE-18368D2FFBBD

Q34341759-02973E5A-EB86-4B52-BB00-538648AC323F

Q34341759-0E8F73F4-0BFC-46AC-9D8A-ACEC67AE2B5A

Q34341759-2E3E4D1A-BBAB-4048-8743-A3909E3CB77E

Q34341759-3FA8A5D5-6CF7-40B0-A323-BFD7C7BB9067

Q34341759-47077719-6EB7-490D-A424-EA6584F27730

Q34341759-5C38801A-B06E-44DA-86A8-902D674471E2

Q34341759-6E69AB4B-2EDA-42CC-B37B-6E267B8FC60A

Q34341759-7F2B5F7F-49DC-4861-96C4-16449F3B4980

Q34341759-CB143ED0-2438-42EA-814B-11F1E490E6C4

P2860

Q34341759-0BF5E7A2-EC02-46ED-8AE9-54C813954E9E

Q34341759-0CB29841-3797-46F0-A009-45B9F17B5C0F

Q34341759-1755E92E-43F4-48DC-91C3-968D54E95C24

Q34341759-17DEE497-A004-4967-8D88-615889058D4D

Q34341759-182973E4-9EA7-4590-9017-8C034F071847

Q34341759-1A9932D1-8F5A-41ED-9207-83D19E63079A

Q34341759-1CB9BFAA-7BDB-4A94-9811-14DAA069AB6F

Q34341759-21EE003A-6B85-4E0A-8D20-B9513B8B3DF8

Q34341759-389842FD-6635-4D2F-8F04-40CBA3204EF2

Q34341759-399A61FA-3CC1-4E0E-8EB0-C312968FA1B3

P304

Q34341759-F3BAC5A9-8BA0-4E51-A3D7-F2EA2F3D5068

P31

Q34341759-136B6EDE-7657-4F45-A87C-1227673C1113

P356

Q34341759-A39BC0D4-867A-476C-A3F6-FA874E09DABB

P407

Q34341759-AD935306-A052-4884-96E2-2EC3DA046B95

P433

Q34341759-657CFA1A-4632-49F3-A405-D8BEDDEA2EA8

P478

Q34341759-1E1F7F23-E856-45B8-8628-E6656413FEDE

P50

Q34341759-49E62C52-4558-4D72-BEA9-DED396082CE5

Q34341759-4BF74993-FD7D-4EBA-AC4C-F320FCEF4270

Q34341759-60F36B79-8DA7-48B7-B424-F846FF3F22B9

Q34341759-9BA97F16-D2B9-4328-97D9-33B4A93EA732

Q34341759-A14A3975-F5C9-4AE5-92EE-03AF70CEDF29

Q34341759-F3FA5B52-29D0-488D-876A-609FB38571FD

Q34341759-FE58455F-05FD-4D37-8AC7-FAE14685AFF9

P577

Q34341759-B74B55E6-4C5B-4675-8856-2B92FB90ACA7

P5875

Q34341759-542025B9-0B1F-4A96-AF76-C2BE598A2327

P698

Q34341759-11B2A6BA-8DA5-4781-B501-46A8B86B01CD

P921

Q34341759-B9E8CB63-B496-4277-833B-42C2B4B01DBB

Q34341759-C5C34719-55EE-4302-AD61-1552A3BF39BD

Q34341759-CEAB4FEA-8C99-43BA-9CD3-066EC4F36502

P932

Q34341759-BCE9CA2F-FB2E-4693-B6B6-47BB8DB08332

P356

JOURNAL.PONE.0040074

P1433

P1476

Sustained exendin-4 secretion ...... els of obesity/type 2 diabetes

@en

P2093

Andrea Cozzi

http://www.w3.org/2001/XMLSchema#string

Carlo M Rotella

http://www.w3.org/2001/XMLSchema#string

Changyu Zheng

http://www.w3.org/2001/XMLSchema#string

Claudio Pagano

http://www.w3.org/2001/XMLSchema#string

Drew G Michael

http://www.w3.org/2001/XMLSchema#string

Edoardo Mannucci

http://www.w3.org/2001/XMLSchema#string

Giovanni Di Pasquale

http://www.w3.org/2001/XMLSchema#string

John A Chiorini

http://www.w3.org/2001/XMLSchema#string

Lorenzo Cinci

http://www.w3.org/2001/XMLSchema#string

Maria E Manni

http://www.w3.org/2001/XMLSchema#string

P2860

Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.

Effect of gene therapy on visual function in Leber's congenital amaurosis

Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis

Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer

Systemic delivery of bioactive glucagon-like peptide 1 after adenoviral-mediated gene transfer in the murine salivary gland.

Adeno-associated virus-mediated gene transfer

Human parathyroid hormone is secreted primarily into the bloodstream after rat parotid gland gene transfer.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Gene therapy using adeno-associated virus vectors

P304

e40074

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0040074

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Annamaria Morelli

Ilaria Dicembrini

Josephine M Egan

P577

2012-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229162139

http://www.w3.org/2001/XMLSchema#string

P698

22808093

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3396615

http://www.w3.org/2001/XMLSchema#string